SR Mitomycin Intravesical Solution

**Semantic type:** Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance

**Definition:** A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of SR mitomycin intravesical solution , the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in SR mitomycin intravesical solution (UGN-102) the strength of MMC is lower.

**Synonyms:** - Intravesical Mitomycin Gel UGN-102 - MMC + UG-1 Gel - Mitomycin Intravesical Solution - Mitomycin Urothelial Gel UGN-102 - RTGel with Mitomycin C UGN-102 - Sustained-release Mitomycin C Hydrogel Formulation UGN-102 - UGN 102 - UGN-102 - UGN102 - Vesigel - Zusduri